Sirnaomics (FRA:V5Z) 3-Month Share Buyback Ratio: 0.00% (As of Jun. 2026 )

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:V5Z Sirnaomics Ltd FRA:V5Z
16 GF Score
Price €0.39
! 4 Warning Signs
View Full Analysis

What is Sirnaomics 3-Month Share Buyback Ratio?

Sirnaomics FRA:V5Z -1.48% 16 3-Month Share Buyback Ratio is 0.00 as of Jun. 2026. GuruFocus rates FRA:V5Z with a GF Score™ of 16/100. The stock has 4 warning signs investors should review.

3-Month Share Buyback Ratio only apply to companies whose reporting frequency is 3 months.

FRA:V5Z
16GF Score
Sirnaomics Ltd FRA:V5Z
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a 3-Month Share Buyback Ratio of 0.00 mean?
Sirnaomics (FRA:V5Z) has a 3-Month Share Buyback Ratio of 0.00 as of Jun. 2026. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Sirnaomics and its competitors.
Is Sirnaomics' 3-Month Share Buyback Ratio too high?
Sirnaomics' current 3-Month Share Buyback Ratio is 0.00. Overall, Sirnaomics has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Sirnaomics' 3-Month Share Buyback Ratio compare to VRTX and REGN?
Sirnaomics' 3-Month Share Buyback Ratio of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Biotechnology company?
A good 3-Month Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Sirnaomics and its competitors. Sirnaomics's current 3-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sirnaomics stock overvalued right now?
Sirnaomics (FRA:V5Z) has a current 3-Month Share Buyback Ratio of 0.00. The current 3-Month Share Buyback Ratio is 0.00. Sirnaomics' overall GF Score™ is 16/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Sirnaomics (FRA:V5Z), the current 3-Month Share Buyback Ratio is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sirnaomics Business Description

Other Exchanges 02257:Hong Kong
Address No.218 Xinghu Street, Unit 415, A4 Building, Suzhou Industrial Park, Suzhou, CHN
Sirnaomics Ltd is a clinical-stage biopharmaceutical company focused on the discovery and development of RNA interference (RNAi) therapeutics for indications with significant unmet medical need. Its pipeline includes candidates such as STP705 for oncology and fibrosis indications, STP707 for solid tumors, and STP122G and STP125G for cardiovascular and metabolic conditions, among others. The company operates research and development activities in both the United States and mainland China, with its non-current assets located in those regions. Sirnaomics generates revenue from mainland China, though as a clinical-stage company its income is limited relative to its development spending. Its therapeutic focus spans oncology, fibrosis, and cardiovascular disease, targeting large markets. The company is headquartered in China and trades on the Hong Kong Stock Exchange.
16GF Score

Get the complete analysis for FRA:V5Z

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.39
Price